Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Oct;18(4):529–533. doi: 10.1111/j.1365-2125.1984.tb02500.x

Comparative bioavailability of tetracycline and lymecycline.

G Sjölin-Forsberg, J Hermansson
PMCID: PMC1463615  PMID: 6487493

Abstract

The relative bioavailability of lymecycline and tetracycline hydrochloride was compared in 12 healthy volunteers in a double-blind cross-over study using a high performance liquid chromatographic method for plasma and urine analyses. A statistical significant difference in favour of tetracycline hydrochloride was found concerning the mean AUC and the mean lag time. The relative bioavailability of lymecycline was only 70% compared with tetracycline in multiple dosing (19.13 +/- 5.39 micrograms ml-1 h and 27.22 +/- 6.26 micrograms ml-1 h respectively) and 80% in a single dose (21.88 +/- 4.23 micrograms ml-1 h and 26.91 +/- 6.01 respectively) and the mean lag time of tetracycline was only 60% compared with lymecycline.

Full text

PDF
529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adir J., Barr W. H. Dose-dependent bioavailability of tetracycline in man. J Pharmacokinet Biopharm. 1978 Apr;6(2):99–110. doi: 10.1007/BF01117445. [DOI] [PubMed] [Google Scholar]
  2. Ariëns E. J., Hanselaar A. G., Henderson P. T., Simonis A. M. Beware of formaldehyde in disguise. Eur J Clin Pharmacol. 1982 Oct;23(4):373–375. doi: 10.1007/BF00613624. [DOI] [PubMed] [Google Scholar]
  3. Barr W. H., Gerbracht L. M., Letcher K., Plaut M., Strahl N. Assessment of the biologic availability of tetracycline products in man. Clin Pharmacol Ther. 1972 Jan-Feb;13(1):97–108. doi: 10.1002/cpt197213197. [DOI] [PubMed] [Google Scholar]
  4. Brice G. W., Hammer H. F. Therapeutic nonequivalence of oxytetracycline capsules. JAMA. 1969 May 19;208(7):1189–1190. [PubMed] [Google Scholar]
  5. Colaizzi J. L., Klink P. R. pH-Partition behavior of tetracyclines. J Pharm Sci. 1969 Oct;58(10):1184–1189. doi: 10.1002/jps.2600581003. [DOI] [PubMed] [Google Scholar]
  6. Flatberg P. Absorpsjon av tetracykliner. Tidsskr Nor Laegeforen. 1973 May 10;93(13):945–946. [PubMed] [Google Scholar]
  7. Gomeni C., Gomeni R. IGPHARM: interactive graphic package for pharmacokinetic analysis. Comput Biomed Res. 1978 Aug;11(4):345–361. doi: 10.1016/0010-4809(78)90017-4. [DOI] [PubMed] [Google Scholar]
  8. Hendrick D. J., Lane D. J. Occupational formalin asthma. Br J Ind Med. 1977 Feb;34(1):11–18. doi: 10.1136/oem.34.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hermansson J., Andersson M. Reversed-phase ion-pair chromatography of tetracycline, tetracycline analogs, and their potential impurities. J Pharm Sci. 1982 Feb;71(2):222–229. doi: 10.1002/jps.2600710221. [DOI] [PubMed] [Google Scholar]
  10. Hermansson J. Rapid determination of tetracycline and lumecycline in human plasma and urine using high-performance liquid chromatography. J Chromatogr. 1982 Nov 12;232(2):385–393. doi: 10.1016/s0378-4347(00)84178-x. [DOI] [PubMed] [Google Scholar]
  11. Perera F., Petito C. Formaldehyde: a question of cancer policy? Science. 1982 Jun 18;216(4552):1285–1291. doi: 10.1126/science.7079759. [DOI] [PubMed] [Google Scholar]
  12. Schorr W. F., Keran E., Plotka E. Formaldehyde allergy. The quantitative analysis of American clothing for free formaldehyde and its relevance in clinical practice. Arch Dermatol. 1974 Jul;110(1):73–76. doi: 10.1001/archderm.110.1.73. [DOI] [PubMed] [Google Scholar]
  13. Tuomisto J., Männistö P. Cross-over study of ten tetracycline preparations. Eur J Clin Pharmacol. 1973 Jun;6(1):64–68. doi: 10.1007/BF00561804. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES